

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS

TI SV40 **tumor** rejection induced by vesicular stomatitis **virus** bearing SV40 **tumor**-specific transplantation antigen (SV40-TSTA). I. Specificity of immunoprotection and effect of enzyme treatment on TSTA activity

AU Ansel, Sandra; Huet, Christian; Tournier, Paul

AB Highly purified vesicular stomatitis virus (**VSV**) was obtained from **VSV**-infected SV40-transformed hamster cell lines. Immunization with **VSV** protected hamsters against challenge with SV40-transformed cells. This protection was obtained regardless of the source of the SV40-transformed cells (e.g. cat, rat, hamster) used to produce **VSV**, and was therefore assocd. with the SV40 tumor-specific transplantation antigen (SV40-TSTA). Furthermore, when grown on spontaneously transformed cell lines or on cells transformed by a different oncogenic DNA virus, such as polyoma virus, the **VSV** failed to protect against the SV40-induced tumor. It was concluded that the SV40-TSTA activity of purified **VSV** is due to the incorporation of SV40-TSTA within the viral envelope. When **VSV** was treated with proteolytic enzymes (bromelain, trypsin) no loss of TSTA-induced tumor rejection was obsd., although **VSV** had lost its ability to induce virus-neutralizing antibody. This clearly demonstrates that the TSTA activity is not related to the viral spikes. Phospholipase C suppressed the TSTA activity but neutralizing activity was still detectable in the anti-**VSV** serums. Thus, the protection afforded by **VSV** is highly specific.

AN 1977:532118 CAPLUS

DN 87:132118

TI SV40 **tumor** rejection induced by vesicular stomatitis **virus** bearing SV40 **tumor**-specific transplantation antigen (SV40-TSTA). I. Specificity of immunoprotection and effect of enzyme treatment on TSTA activity

AU Ansel, Sandra; Huet, Christian; Tournier, Paul

CS Inst. Rech. Sci. Cancer, Villejuif, Fr.

SO International Journal of Cancer (1977), 20(1), 51-60
CODEN: IJCNAW; ISSN: 0020-7136

DT Journal

LA English

L6 ANSWER 29 OF 41 MEDLINE DUPLICATE 14
TI **Oncolytic viruses.**
AU Nemunaitis J
AB Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been limited to injection site pain, transient fever and tumor necrosis. Responses with early crude materials were usually short in duration; however, recent trials with gene attenuated viruses suggest more prolonged duration to responses observed.
AN 2000221158 MEDLINE
DN 20221158 PubMed ID: 10759404
TI **Oncolytic viruses.**
AU Nemunaitis J
CS PRN Research, Inc., Dallas, TX, USA.
SO INVESTIGATIONAL NEW DRUGS, (1999) 17 (4) 375-86. Ref: 128
Journal code: 8309330. ISSN: 0167-6997.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 200004
ED Entered STN: 20000512
Last Updated on STN: 20000512
Entered Medline: 20000428

L6 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2002 ACS
TI Replicating **oncolytic viruses**: an overview
AU Kirn, David H.
AB Unavailable
AN 1996:375798 CAPLUS
TI Replicating **oncolytic viruses**: an overview
AU Kirn, David H.
CS Onyx Pharmaceuticals, Richmond, CA, USA
SO Expert Opin. Invest. Drugs (1996), 5(6), 753-762
CODEN: EOIDER; ISSN: 0967-8298
DT Journal
LA English

L6 ANSWER 31 OF 41 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
TI **ONCOLYTIC VIRUSES AND VIRAL ONCOLYSATES NEW IDEAS.**
AU SINKOVICS J G
AN 1991:194445 BIOSIS
DN BR40:91725
TI **ONCOLYTIC VIRUSES AND VIRAL ONCOLYSATES NEW IDEAS.**
AU SINKOVICS J G
CS COMMUNITY CANCER CENT., ST. JOSEPH'S HOSP., TAMPA, FLA.
SO 15TH INTERNATIONAL CANCER CONGRESS, HAMBURG, GERMANY, AUGUST 16-22, 1990.
J CANCER RES CLIN ONCOL. (1990) 116 (SUPPL PART 2), 1094.
CODEN: JCROD7. ISSN: 0171-5216.
DT Conference
FS BR; OLD
LA English